Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis

Autoimmunity Reviews

Volumn 13, Issue 6, 2014, Pages 595-608

  Reynaud, Quitterie ^a   Lega, Jean Christophe ^b,c   Mismetti, Patrick ^a,c   Chapelle, Céline ^a,d   Wahl, Denis ^e,f   Cathébras, Pascal ^a   Laporte, Silvy ^a,c,d  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ LYON 1   (France)

^c University Jean Monnet of Saint Etienne EA3065   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Anti phospholipid antibodies; Antiphospholipid syndrome; Arterial thrombosis; Deep venous thrombosis; Meta analysis; Pulmonary embolism

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHATIDYL ETHANOLAMINE ANTIBODY; PHOSPHATIDYL SERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ANTI-PHOSPHOLIPID ANTIBODIES; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOSIS; DEEP VENOUS THROMBOSIS; META-ANALYSIS; PULMONARY EMBOLISM;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; THROMBOSIS;

EID: 84896537523     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.11.004     Document Type: Review

References (66)

1. Finazzi G., Brancaccio V., Moia M., Ciaverella N., Mazzucconi M.G., Schinco P.C., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530-536.
2. Reitsma P.H., Versteeg H.H., Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012, 32:563-568.
3. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000, 15:145-151.
4. Wahl D.G., Bounameaux H., de Moerloose P., Sarasin F.P. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000, 160:2042-2048.
5. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I., Brey R., Crowther M., Derksen R., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011, 20:206-218.
6. Wahl D.G., Guillemin F., de Maistre E., Perret-Guillaume C., Lecompte T., Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998, 7:15-22.
7. Pierangeli S.S., Favaloro E.J., Lakos G., Meroni P.L., Tincani A., Wong R.C.W., et al. Standards and reference materials for the anticardiolipin and anti-β(2)glycoprotein I assays: a report of recommendations from the APL task force at the 13th International Congress on antiphospholipid antibodies. Clin Chim Acta 2012, 18:1-2.
8. Lakos G., Favaloro E.J., Harris E.N., Meroni P.L., Tincani A., Wong R.C., et al. International consensus guidelines on anticardiolipin and anti-β(2) glycoprotein I testing: a report from the APL task force at the 13(th) international congress on antiphospholipid antibodies. Arthritis Rheum 2012, 64:1-10.
9. Arnout J., Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003, 1:931-942.
10. De Groot P.G., Horbach D.A., Simmelink M.J., van Oort E., Derksen R.H. Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. Lupus 1998, 7(Suppl. 2):S32-S36.
11. Sanmarco M., Boffa M.-C. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus 2009, 18:920-923.
12. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003, 102:2717-2723.
13. Alessandri C., Conti F., Pendolino M., Mancini R., Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011, 10:609-616.
14. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317.
15. Cervera R., Conti F., Doria A., Iaccarino L., Valesini G. Does seronegative antiphospholipid syndrome really exist?. Autoimmun Rev 2012, 11:581-584.
16. Staub H.L., Bertolaccini M.L., Khamashta M.A. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 2012, 12:230-234.
17. Meijide H., Sciascia S., Sanna G., Khamashta M.A., Bertolaccini M.L. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 2013, 12:421-425.
18. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
19. Deeks J., Altman D., Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in health care. Meta-analysis in context 2001, Egger M, London.
20. http://www.spc.univ-lyon1.fr/easyma.net.EasyMA.net.n.d.
21. Bongard O., Reber G., Bounameaux H., de Moerloose P. Anticardiolipin antibodies in acute venous thromboembolism. Thromb Haemost 1992, 67:724.
22. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997-1002.
23. Fijnheer R., de Walk B., Punt J., Muller H.P. Antiphospholipid antibodies in patients with thrombo-embolic disease. Lupus 1994, 3:361.
24. Simioni P., Zanon E., Prandoni P., Saracino M.A., Cogo A. Lupus anticoagulant and antiphospholipid antibodies in outpatients with clinically suspected DVT. Lupus 1994, 3:361.
25. Ginsberg J.S., Wells P.S., Brill-Edwards P., Donovan D., Moffatt K., Johnston M., et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995, 86:3685-3691.
26. Simioni P., Prandoni P., Zanon E., Saracino M.A., Scudeller A., Villalta S., et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996, 76:187-189.
27. Palosuo T., Virtamo J., Haukka J., Taylor P.R., Aho K., Puurunen M., et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men-a nested case-control study. Thromb Haemost 1997, 78:1178-1182.
28. Sanmarco M., Alessi M.C., Harle J.R., Sapin C., Aillaud M.F., Gentile S., et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001, 85:800-805.
29. Runchey S.S., Folsom A.R., Tsai M.Y., Cushman M., McGovern P.D. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002, 119:1005-1010.
30. Previtali S., Barbui T., Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. Thromb Haemost 2002, 88:729-732.
31. De Groot P.G., Lutters B., Derksen R.H.W.M., Lisman T., Meijers J.C.M., Rosendaal F.R. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005, 3:1993-1997.
32. Naess I.A., Christiansen S.C., Cannegieter S.C., Rosendaal F.R., Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006, 4:44-49.
33. Hirmerova J., Ulcova-Gallova Z., Seidlerova J., Filipovsky J., Bibkova K., Micanova Z., et al. Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 2010, 16:318-325.
34. Kushner M.J. Prospective study of anticardiolipin antibodies in stroke. Stroke 1990, 21:295-298.
35. Chakravarty K.K., Byron M.A., Webley M., Durkin C.J., al-Hillawi A.H., Bodley R., et al. Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients without systemic lupus erythematosus. Q J Med 1991, 79:397-405.
36. Hess D.C., Krauss J., Adams R.J., Nichols F.T., Zhang D., Rountree H.A. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 1991, 41:525-528.
37. The Antiphospholipid Antibodies in Stroke Study (APASS) Group Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993, 43:2069-2073.
38. Muir K.W., Squire I.B., Alwan W., Lees K.R. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994, 344:452-456.
39. Camerlingo M., Casto L., Censori B., Drago G., Frigeni A., Ferraro B., et al. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 1995, 92:69-71.
40. Metz L.M., Edworthy S., Mydlarski R., Fritzler M.J. The frequency of phospholipid antibodies in an unselected stroke population. Can J Neurol Sci 1998, 25:64-69.
41. Tuhrim S., Rand J.H., Wu X.X., Weinberger J., Horowitz D.R., Goldman M.E., et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999, 30:1561-1565.
42. Tuhrim S., Rand J.H., Wu X., Horowitz D.R., Weinberger J., Goldman M.E., et al. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 1999, 53:1523-1527.
43. Brey R.L., Stallworth C.L., McGlasson D.L., Wozniak M.A., Wityk R.J., Stern B.J., et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002, 33:2396-2400.
44. Palomo I., Pereira J., Alarcón M., Vásquez M., Pinochet C., Vélez M.T., et al. Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clin Rheumatol 2004, 23:129-133.
45. Lien L.-M., Chen W.-H., Chiu H.-C., Pan W.-H., Chen J.-R., Bai C.-H. High titer of anticardiolipin antibody is associated with first-ever ischemic stroke in Taiwan. Cerebrovasc Dis 2006, 22:225-230.
46. Meroni P.L., Peyvandi F., Foco L., Bernardinelli L., Fetiveau R., Mannucci P.M., et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007, 5:2421-2428.
47. Saidi S., Mahjoub T., Almawi W.Y. Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke. J Thromb Haemost 2009, 7:1075-1080.
48. Urbanus R.T., Siegerink B., Roest M., Rosendaal F.R., de Groot P.G., Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009, 8:998-1005.
49. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of anticoagulation study group. Am J Med 1998, 104:332-338.
50. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L.P., Sacco R.L., Sciacca R.R., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
51. Mirarabshahi P., Abdelatti M., Krilis S. Post-translational oxidative modification of β2-glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome. Autoimmun Rev 2012, 11:779-780.
52. Chamorro A.-J., Marcos M., Mirón-Canelo J.-A., Cervera R., Espinosa G. Val247Leu β2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. Autoimmun Rev 2012, 11:705-712.
53. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet 2010, 376:1498-1509.
54. Prandoni P., Piovella C., Pesavento R. Venous thromboembolism and arterial complications. Semin Respir Crit Care Med 2012, 33:205-210.
55. Bruce I.N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol 2005, 19:823-838.
56. Finazzi G. Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders. Lupus 2012, 21:747-750.
57. Pengo V., Banzato A., Denas G., Jose S.P., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834.
58. Vila P., Hernández M.C., López-Fernández M.F., Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994, 72:209-213.
59. Girón-González J.A., García del Río E., Rodríguez C., Rodríguez-Martorell J., Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004, 31:1560-1567.
60. Forastiero R., Martinuzzo M., Pombo G., Puente D., Rossi A., Celebrin L., et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005, 3:1231-1238.
61. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718.
62. Erkan D., Harrison M.J., Levy R., Peterson M., Petri M., Sammaritano L., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007, 56:2382-2391.
63. Ceccarelli F., Chighizola C., Finazzi G., Meroni P.L., Valesini G. Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". Autoimmun Rev 2012, 11:568-571.
64. Arnaud L., Mathian A., Ruffatti A., Erkan D., Tektonidou M., Cervera R., et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014, 13(3):281-291.
65. Tozzoli R., Villalta D. Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev 2014, 13:59-63.
66. Roggenbuck D., Egerer K., von Landenberg P., Hiemann R., Feist E., Burmester G.-R., et al. Antiphospholipid antibody profiling: time for a new technical approach?. Autoimmun Rev 2012, 11:821-826.